A florist has shared the perfect Valentine's flower for every zodiac sign - so you can get your date the perfect bouquet for ...

Eli Lilly, BCE, Suncor, Canada Goose ... said revenue for the three months ended Dec. 31 rose to $3.11 billion from $3.06 billion in the same period in 2023. On an adjusted basis, Bombardier ...

If you’re on the hunt for the best bulbs to plant in February for pink blooms this year, there’s a long list of tubers, bulbs ...

Unfolding the Rich Tapestry of Flower Tattoo Symbolism. Flowers have long held a captivating allure, enchanting us with their ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same period in 2023.

Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier. Mounjaro's revenue rose to $3.53 billion. Lilly's stock climbed more than 2% Thursday morning.

The unit came into being thanks to an endowment from Young, a Purdue chemical engineering alumnus who had a long career at Lilly and eventually rose to become head of manufacturing at Genentech ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...